logo
Sign in

TBPH Stock Price, Chart, Stats & News

Theravance Biopharma, Inc.
Save
874.85M
Market cap
7.61x
Current P/E
7.75x
Forward P/E

TBPH chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
94.87%
Operating margin
-12.33%
Pretax margin
120.27%
Net margin
98.54%
Effective tax rate
18.07%
ROA
21.81%
ROE
46.03%
D/E
0.25x
Interest coverage ratio
-5.38x

TBPH valuation

P/E
7.61x
P/S
7.23x
P/B
2.59x
P/CF
3.22x
P/FCF
3.26x
P/OCF
3.22x
PEG
0.03x
EV multiple
1050.57x

About

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.

Similar securities

Based on sector and market capitalization

Report issue